CRISTINA BARNES: Open Payments
NPI 1548934219 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,476 in 104 payments from 16 companies in 2025. Trend: 2023 $2,704 · 2024 $2,084 · 2025 $3,476
Food & beverage: $2,392Consulting: $1,050Education: $34
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 8 | $1,161 |
| AstraZeneca Pharmaceuticals LP | 24 | $671 |
| GENZYME CORPORATION | 25 | $650 |
| GlaxoSmithKline, LLC. | 11 | $181 |
| Grifols USA, LLC | 7 | $166 |
| Novartis Pharmaceuticals Corporation | 5 | $162 |
| CSL Behring | 6 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $73 |
| PFIZER INC. | 3 | $52 |
| Galderma Laboratories, L.P. | 3 | $47 |
Products named: DUPIXENT, FASENRA, Xembify, AIRSUPRA, NUCALA, Hizentra, AYVAKIT, TEZSPIRE.
Industry payments across OK — which companies pay providers there.
